Table 3. Multivariable associations between longer donor RTL (using the 25th percentile as a cut-off point) and HCT outcomes in the discovery and validation cohorts.
| Outcome | Discovery cohort* N=300 | 1st Validation* N=297 | 2nd validation# N=488 |
|---|---|---|---|
| HR (95% CI) P | |||
| OS | 0.73 (0.52-1.03) 0.08 | 0.94 (0.65-1.38) 0.76 | 1.25 (0.91-1.71) 0.17 |
| DFS | 0.73 (0.52-1.03) 0.07 | 0.92 (0.63-1.34) 0.66 | 1.18 (0.87-1.59) 0.29 |
| TRM | 0.80 (0.49-1.32) 0.38 | 0.82 (0.48-1.43) 0.49 | 1.23 (0.77-1.98) 0.38 |
| Relapse | 0.62 (0.38-1.00) 0.05 | 1.20 (0.69-2.07) 0.51 | 1.12 (0.76-1.66) 0.56 |
| aGVHD II-IV | 0.68 (0.46-1.00) 0.05 | 1.00 (0.66-1.51) 0.99 | 1.00 (0.73-1.38) 0.98 |
| aGVHD III-IV | 0.62 (0.34-1.14) 0.13 | 1.10 (0.53-2.30) 0.79 | 1.24 (0.71-2.16) 0.46 |
| cGVHD | 1.06 (0.72-1.56) 0.77 | 0.98 (0.67-1.45) 0.93 | 0.99 (0.74-1.34) 0.97 |
| Neutrophil engraftment | 1.30 (0.99-1.71) 0.06 | 0.84 (0.63-1.11) 0.21 | 1.24 (1.00-1.54) 0.05 |
OS models are adjusted for: recipient age, donor age; DFS adjusted for CMV match, KPS, donor age; TRM for time from diagnosis to HCT, KPS, recipient age, year of HCT, donor age; Relapse for donor age, TBI, DPB1 TCE match, Sex; aGVHD II-IV for ATG, graft type, donor age; aGVHD III-IV for ATG, disease status, donor age; cGVHD for ethnicity, graft type, recipient blood type, year of HCT, donor age; Engraftment for graft type, TBI, donor age
OS models are adjusted for: recipient age, donor age and use of TBI; stratified by graft type and ABO match; DFS: recipient age, graft type, donor age and use of TBI; stratified by patient ABO type; TRM: recipient age, graft type, donor age and use of TBI; stratified by graft type and ABO match; Relapse: donor age; aGVHD II-IV: ATG, use of alemtuzumab, donor age, GVHD prophylaxis, donor age and recipient age; aGVHD III-IV: donor age; cGVHD: ABO match, ATG, use of alemtuzumab, graft type, TCE match, use of TBI, donor age and year of transplant; Engraftment: ABO match, donor age and use of TBI; stratified by graft type